GSK is back on level pegging with its rivals in the RSV vaccine category in the US, after getting FDA approval for Arexvy in the 18 to 49 age bracket.
CMS innovation center to expand team focused on drug prices
To help with new pilot models aimed at lowering drug costs across Medicaid and Medicare, CMS’ innovation center is ramping up staff. “We are on


